Bulk order Acrobiosystems for Chinese

Chinese

A-Z

SARS-CoV-2 | CD24 | CD73 | Trimer | CD19 | PD-1

There is no goods in the shopping cart !

My Cart

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9

Home
Product & Service

Products by Category

Recombinant proteins and more
FDA DMF Filed ProteinsHot SARS-CoV-2 Related ProductsHot Immune Checkpoint ProteinsHot Targets of CAR-T Cell TherapyNew Biosimilar Drug TargetsHot Tumor MicroenvironmentHot Anti-idiotypic AntibodyHot Fc Receptor Proteins Llama IgG Fc Fusion ProteinNew Bio-Markers & CD Antigens ActiveMax -Best Cytokines Viral Proteins Enzymes Antibodies All Recombinant Proteins
Services

Innovation Lab ServicesNew SPR /BLI analytical serviceNew

Pre-labeled proteins
Biotinylated protein collectionHot FITC & PE labeled ProteinsNew Fluorescent fusion proteins
Kits
SARS-CoV-2 Related Kit ProductsNew Pre-Coupling Magnetic BeadsNew Universal ELISA KitsNew ELISA Assay Kits for Quantitative Analysis of Therapeutic Antibodies in Serum SamplesNew Inhibitor Screening Kits
Others
HPLC-verified Proteins Integrin - Integrin Proteins BCMA - B-Cell Maturation Antigen TIGIT - TIGIT Signaling Axis CD24 & Siglec-10 proteinsHot

Hot Products

Supports on COVID-19 R&D
Reagents for vaccine developmentNew Reagents for diagnostic developmentNew SARS-CoV-2 related productsNew SARS-CoV-2 related kitsNew SARS-CoV-2 spike mutantsNew
Others
Bispecific antibody targetsHot Targets for ADCsHot IL-2 ReceptorsHot CD19 proteinsHot Anti-FMC63 mAbHot CD3 proteinsHot B7 family proteinsHot TNFSF proteinsHot VEGF proteinsHot CD39/CD73 proteinsNew Siglec-15 proteinsHot CD20 proteinsExclusive PD1 proteinsHot
Support

How to Order Shipping & Payments Global Distributors Testimonials Download Brochures Download COA
Application

The Process of How SARS-CoV-2 Infects the Host Quantitative Analysis of mAb in Serum Evaluation of CAR Expression
X-LAB
Company

About Us Join Us Contact Us
Activities

News Exhibitions Promotion
COVID-19 R&D ^New

Your Position: Home > IDH1

IDH1

IDH1 Molecule Information

Name:Isocitrate dehydrogenase [NADP] cytoplasmic
Target Synonym:Isocitrate Dehydrogenase [NADP] Cytoplasmic,IDH,EC 1.1.1.42,HEL-216,HEL-S-26,IDH1,Cytosolic NADP-Isocitrate Dehydrogenase,NADP(+)-Specific ICDH,IDP,Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic,IDCD,PICD,Isocitrate Dehydrogenase 1 (NADP+), Soluble,Isoci

Number of Launched Drugs:1
Number of Drugs in Clinical Trials:9
Lastest Research Phase:Approved

IDH1 Molecule Synonym Name

IDH1,PICD,IDP

IDH1 Molecule Background

Isocitrate dehydrogenase 1 (IDH1) is also known as Cytosolic NADP-isocitrate dehydrogenase (NADP(+)-specific ICDH), Oxalosuccinate decarboxylase and PICD, which is one of the Isocitrate dehydrogenases that can catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. These enzymes belong to two distinct subclasses, one of which utilizes NAD+ as the electron acceptor and the other NADP+. The cytoplasmic enzyme serves a significant role in cytoplasmic NADPH production.

IDH1 References

IDH1 Public Drug Information

Name	Research Code	Research Phase	Company	First Brand Name	First Approved Country	First Indication	First Approved Company	First Approved Date	Indications	Clinical Trials
Ivosidenib	AG-120; CS-3010	Approved	Celgene Corp, Agios Pharmaceuticals	Tibsovo	United States	Leukemia, Myeloid, Acute	s:25:"Agios Pharmaceuticals Inc";	2018-07-20	Leukemia; Chondrosarcoma; Biliary Tract Neoplasms; Leukemia, Myeloid; Solid tumours; Myelodysplastic Syndromes; Cholangiocarcinoma; Hepatic Insufficiency; Bile Duct Neoplasms; Leukemia, Myeloid, Acute; Glioma	Details

IDH1 Clinical Drug Information

Name	Research Code	Research Phase	Company	Indications	Clinical Trials
IDH1 peptide vaccine (German Cancer Research Center)		Phase 1 Clinical	Deutsches Krebsforschungszentrum, Dkfz	Glioma	Details
DS-1001	DS-1001b; DS-1001	Phase 2 Clinical	Daiichi Sankyo Co Ltd	Glioma	Details
Olutasidenib	FT-2102	Phase 2 Clinical	Forma Therapeutics	Chondrosarcoma; Irritable Bowel Syndrome; Clostridium Infections; Myelodysplastic Syndromes; Glioblastoma; Diarrhea; Leukemia, Myeloid, Acute; Glioma	Details
HMPL-306	HMPL-306	Phase 1 Clinical	Hutchison Medipharma Ltd	Hematologic Neoplasms; Solid tumours; Leukemia, Myeloid, Acute	Details
HH-2301		Phase 1 Clinical		Chondrosarcoma; Biliary Tract Neoplasms; Solid tumours; Glioma	Details
TQB-3455	TQB-3455	Phase 1 Clinical	Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd, Beijing Sailintai Medicine Technology Co Ltd	Solid tumours; Hematologic Neoplasms; Leukemia, Myeloid, Acute	Details
LY-3410738	LY-3410738	Phase 1 Clinical	Eli Lilly And Company	Chondrosarcoma; Solid tumours; Myelodysplastic Syndromes; Myeloproliferative Disorders; Leukemia, Myelomonocytic, Chronic; Cholangiocarcinoma; Leukemia, Myeloid, Acute; Glioma	Details
Vorasidenib	AG-881	Phase 3 Clinical	Celgene Corp, Agios Pharmaceuticals	Hematologic Neoplasms; Biliary Tract Neoplasms; Myelodysplastic Syndromes; Sarcoma; Leukemia, Myeloid, Acute; Glioma	Details
IDH-305	IDH-305	Phase 2 Clinical	Novartis Pharma Ag	Neoplasms; Leukemia, Myeloid, Acute; Glioma	Details
BAY-1436032	BAY-1436032	Phase 1 Clinical	Bayer Ag	Solid tumours; Leukemia, Myeloid, Acute	Details